What is the function of dasatinib? What types of cancers or diseases is it primarily used to treat?

Dasatinib (Dasatinib) is an oral targeted therapy drug that is a tyrosine kinase inhibitor. It mainly prevents the proliferation and spread of cancer cells by inhibiting tyrosine kinase activity in cancer cells. Dasatinib is particularly effective in treating certain types of hematological cancers and has been widely used in the treatment of many cancers.

The most common indication for dasatinib is chronic myelogenous leukemia (CML). CML is a malignant tumor originating from the bone marrow and is often associated with BCR-ABL gene mutations. Dasatinib effectively prevents the proliferation of cancer cells and inhibits the growth of leukemia cells by inhibiting the activity of BCR-ABL fusion protein. It is particularly suitable for patients with CML who are resistant to other treatments (such as imatinib), and the treatment effect is often more significant.

Dasatinib is also used to treat acute lymphoblastic leukemia (ALL), especially in BCR-ABL positive patients. Acute lymphoblastic leukemia is a malignant hematological disease common in children and adults. Dasatinib can effectively control and inhibit the progression of ALL by inhibiting the function of BCR-ABL tyrosine kinase. Dasatinib offers an alternative treatment option for patients who have failed traditional chemotherapy.

In addition to CML and ALL, dasatinib has also shown certain potential in the treatment of other cancers. For example, dasatinib has also shown to inhibit tumor growth in the treatment of certain types of solid tumors, such as malignant pleural mesothelioma. Although these indications are not the main therapeutic areas of dasatinib, as a multi-target drug, it can effectively target multiple different tyrosine kinases, thus providing patients with more treatment options.

Dasatinib can be combined with other chemotherapy drugs or targeted drugs to enhance the effectiveness of treatment. For example, dasatinib, when used in combination with other drugs, can increase the response rate to leukemia and help reduce the risk of relapse. During the treatment process, the patient's individualized treatment plan is crucial. The doctor will adjust the dosage of dasatinib or the selection of combined drugs according to the patient's specific situation in order to achieve the best therapeutic effect.

Reference materials:https://go.drugbank.com/drugs/DB01254